Prospective comprehensive profiling of immune responses to COVID-19 vaccination in patients on zanubrutinib therapy.

The RBD antibody seroconversion rate and CD4 + and CD8 + T‐cell responses were higher following heterologous three‐dose vaccination compared to homologous vaccination schedule, but the differences did not reach statistical significance (Table S3 ). 4 DISCUSSION Compared to published literature, the design of our study had three advantageous aspects: (1) patients were enrolled prospectively and tested uniformly; (2) we used a fourfold rise in antibody levels to define serological response, in line with established definitions utilised in influenza vaccination studies [ 9 ]; and (3) T‐cell responses were assessed at all time points.

also in 111,027 other papers